Creatine Monohydrate Tested as Bioenergetic Therapy for Alzheimer's Disease
A completed University of Kansas trial investigates whether creatine monohydrate can support brain energy metabolism in Alzheimer's patients.
Summary
Researchers at the University of Kansas Medical Center completed a clinical trial examining creatine monohydrate as a potential treatment for Alzheimer's disease. The rationale centers on bioenergetics — the brain's energy production systems are impaired in Alzheimer's, and creatine is well known for its role in replenishing cellular energy currency. By supplementing with creatine monohydrate, the study aimed to determine whether restoring or augmenting brain energy reserves could slow cognitive decline or improve function in affected individuals. Creatine is inexpensive, widely available, and has a strong safety record in healthy populations, making it an attractive candidate for repurposing. While detailed results have not yet been published, the completion of this trial represents a meaningful step toward understanding whether metabolic support strategies can meaningfully address neurodegeneration.
Detailed Summary
Alzheimer's disease affects more than 50 million people worldwide and remains one of the most urgent unmet needs in medicine. While much research has focused on amyloid plaques and tau tangles, growing evidence points to mitochondrial dysfunction and impaired cerebral energy metabolism as early and potentially modifiable features of the disease. This bioenergetic failure may accelerate neuronal loss and cognitive decline, making metabolic interventions a compelling therapeutic avenue.
This completed clinical trial, sponsored by the University of Kansas Medical Center and registered under NCT05383833, investigated creatine monohydrate as a strategy to augment brain bioenergetics in individuals with Alzheimer's disease. Creatine plays a central role in the phosphocreatine energy buffer system, rapidly regenerating ATP in high-demand tissues including the brain. Preclinical studies have suggested neuroprotective and cognition-supporting effects of creatine supplementation, and its favorable safety profile in healthy and athletic populations makes it a practical candidate for repurposing in neurodegeneration.
The trial has been listed as completed as of its registration date in December 2022, though full results and peer-reviewed publications have not yet been released based on available information. The phase designation is listed as not applicable, suggesting this may be a feasibility or pilot study rather than a large-scale efficacy trial. Outcomes likely examined markers of brain energy metabolism, cognitive function, and safety tolerability in the Alzheimer's population.
If creatine supplementation is shown to support cerebral bioenergetics, it could represent a low-cost, low-risk adjunct therapy for Alzheimer's management — particularly valuable given the scarcity of disease-modifying treatments. This would also validate the broader hypothesis that energy metabolism is a druggable target in neurodegeneration.
Caveats are significant: only the trial abstract is available, and no outcome data have been reviewed. The study's phase and scale suggest limited statistical power to detect clinical efficacy.
Key Findings
- Trial completed testing creatine monohydrate as a bioenergetic intervention specifically in Alzheimer's disease patients.
- Rationale targets mitochondrial and ATP metabolism dysfunction — an early and potentially reversible feature of Alzheimer's.
- Creatine is low-cost, widely available, and has an established safety record, lowering barriers to clinical translation.
- Full results are not yet published; this summary reflects trial registration data only.
- Success could validate metabolic support as a viable therapeutic strategy in neurodegeneration.
Methodology
This is a completed interventional clinical trial registered on ClinicalTrials.gov (NCT05383833), sponsored by the University of Kansas Medical Center. The intervention is oral creatine monohydrate administered to individuals diagnosed with Alzheimer's disease. Phase is listed as not applicable, suggesting a feasibility, pilot, or mechanistic design rather than a Phase II or III efficacy trial.
Study Limitations
This summary is based on the clinical trial registration abstract only, as full results and peer-reviewed publications are not yet available. No efficacy or safety outcome data could be evaluated. The non-applicable phase designation suggests this may be a small pilot study, limiting generalizability.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.